ClinicalTrials.gg
Not yet recruitingNCT07513857Updated Apr 7, 2026

Trial of JYB1904 Injection in Adolescent Participants

A Phase 1 interventional study of JYB1904 in Allergic Diseases, sponsored by Jemincare. Not yet recruiting. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Jemincare · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Study summary

This Phase Ib Trial is Meant to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of JYB1904 Injection in Adolescent Participants With Allergic Diseases.

Read the detailed description

This Study is a multicenter, single-arm, Phase Ib clinical study to evaluate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity profiles of JYB1904 injection in adolescent participants aged 12-17 years

02

Conditions studied

  • Allergic Diseases

Keywords

  • Allergic Diseases
03

In context

Lead sponsor

Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescent study participants (both male and female) who are at least 12 years of age but under 18 years of age at the time of signing the Form (ICF).
  • History of allergic diseases, including but not limited to food allergies, allergic rhinitis, allergic asthma, and chronic spontaneous urticaria.
  • Body weight ≥ 30 kg at screening.
  • Agreement to use effective during the study and for 1 year following administration of the study drug.
  • The trial participant and their parent or legal guardian are able to understand and voluntarily sign the Informed Consent Form, and are able to comply with study visits and related procedures.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of to JYB1904 Injection, its , or any anti-IgE therapy.
  • Any severe or poorly controlled chronic disease (including but not limited to severe arrhythmia, ischemic heart disease, Class III/IV left ventricular failure, severe pulmonary disease, poorly controlled asthma, poorly controlled hypertension, poorly controlled diabetes, or poorly controlled hypothyroidism or hyperthyroidism) that, in the investigator's judgment, may compromise the safety of the trial participant.
  • History of severe allergic reactions, such as anaphylactic shock.
  • History of blood phobia, needle phobia, or difficulty with venipuncture; or abnormal skin at the administration site that may interfere with drug administration or the investigator's assessment (e.g., skin lesions, rashes, tattoos, etc.).
  • Total blood loss or blood donation of ≥400 mL within 12 weeks prior to screening, or receipt of a blood transfusion within 12 weeks prior to screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    JYB1904 Injection Group

    300 mg JYB1904 injection administered subcutaneously(SC)

    Drug: JYB1904

Interventions

  • Received a single 300 mg JYB1904 injection administered subcutaneously(SC) at D1

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Adverse events (AEs) and serious adverse events (SAEs), vital signs, physical examination, 12-lead electrocardiogram (ECG) and laboratory results

    Time frame: Through study completion, an average of 28 weeks

  2. Pharmacokinetic (PK) profile of JYB1904 injection

    Maximum Concentration(Cmax)

    Time frame: Through study completion, an average of 28 weeks

  3. Pharmacokinetic (PK) profile of JYB1904 injection

    Time to Reach Cmax(Tmax)

    Time frame: Through study completion, an average of 28 weeks

  4. Pharmacokinetic (PK) profile of JYB1904 injection

    Area Under the concentration-time Curve from time zero to the last accurately quantifiable time point(AUC0-t)

    Time frame: Through study completion, an average of 28 weeks

Secondary outcomes

  1. Other PK Parameters

    Terminal Phase Half-life( t1/2)

    Time frame: Through study completion, an average of 28 weeks

  2. Other PK Parameters

    Area Under the concentration-time Curve from time zero to infinity(AUC0-inf)

    Time frame: Through study completion, an average of 28 weeks

  3. Pharmacodynamic (PD) profile of JYB1904 injection

    Changes in serum level of total and free IgE

    Time frame: Through study completion, an average of 28 weeks

  4. Immunogenicity of JYB1904 injection

    Positive detection rate of anti-drug antibodies (ADA)/neutralizing ADA (Nab), ADA onset time, duration, and titer

    Time frame: Through study completion, an average of 28 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Jul 2027, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 7, 2026
StartEst.
May 17, 2026
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07513857
Lead sponsor
Jemincare
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
May 17, 2026 (estimated)
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Apr 7, 2026

Study contacts

Jing Xu
Contact
xujing2@jeyoupharma.com
021-58306003
Liming Wu
principal investigator · First People's Hospital of Hangzhou

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ozureprubart

Start the discussion